Paricalcitol
PARICALCITOL- paricalcitol capsule
Bryant Ranch Prepack
1 INDICATIONS AND USAGE
1.1 Chronic Kidney Disease Stages 3 and 4
Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4.
Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
1.2 Chronic Kidney Disease Stage 5
Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD).
Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
2 DOSAGE AND ADMINISTRATION
2.1 Chronic Kidney Disease Stages 3 and 4 in Adults
Administer paricalcitol capsules orally once daily or three times a week [see Clinical Studies (14.1)]. When dosing three times weekly, do not administer more frequently than every other day.
Initial Dose
Table 1. Recommended Paricalcitol Capsules Starting Dose Based upon Baseline iPTH Level
Baseline iPTH Level | Daily Dose | Three Times a Week Dose* |
Less than or equal to 500 pg/mL | 1 mcg | 2 mcg |
More than 500 pg/mL | 2 mcg | 4 mcg |
*To be administered not more often than every other day |
Dose Titration
Table 2. Recommended Paricalcitol Capsules Dose Titration Base upon iPTH Level
Dose Adjustment at 2 to 4 Week Intervals | |||
iPTH Level Relative to Baseline | Paricalcitol Capsule Dose | Daily Dosage | Three Times a Week Dosage* |
The same, increased or decreased by less than 30% | Increase dose by | 1 mcg | 2 mcg |
Decreased by more than or equal to 30% and less than or equal to 60% | Maintain dose | – | – |
Decreased by more than 60% or iPTH less than 60 pg/mL | Decrease dose by | 1 mcg | 2 mcg |
* To be administered not more often than every other day |
If a patient is taking the lowest dose, 1 mcg, on the daily regimen and a dose reduction is needed, the dose can be decreased to 1 mcg three times a week. If a further dose reduction is required, the drug should be withheld as needed and restarted at a lower dosing frequency.
2.2 Chronic Kidney Disease Stage 5 in Adults
Initial Dose
Administer the dose of paricalcitol capsules orally three times a week, no more frequently than every other day based upon the following formula:
Dose (micrograms) = baseline iPTH (pg/mL) divided by 80
Treat patients only after their baseline serum calcium has been adjusted to 9.5 mg/dL or lower to minimize the risk of hypercalcemia [see Clinical Pharmacology (12.2) and Clinical Studies (14.2)].
Dose Titration
Individualize the dose of paricalcitol based on iPTH, serum calcium and phosphorus levels. Titrate paricalcitol dose based on the following formula:
Dose (micrograms) = most recent iPTH level (pg/ml) divided by 80
If serum calcium is elevated, the dose should be decreased by 2 to 4 micrograms.
As iPTH approaches the target range, small, individualized dose adjustments may be necessary in order to achieve a stable iPTH. In situations where monitoring of iPTH, Ca or P occurs less frequently than once per week, a more modest initial and dose titration ratio (e.g., iPTH divided by 100) may be warranted.
Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
2.4 Monitoring
Monitor serum calcium and phosphorus levels closely after initiation of paricalcitol, during dose titration periods and during co-administration with strong CYP3A inhibitors [see Warnings and Precautions (5.3) , Drug Interactions (7) , and Clinical Pharmacology (12.3)].
If hypercalcemia is observed, the dose of paricalcitol should be reduced or withheld until these parameters are normalized.
2.5 Administration
Paricalcitol capsules may be taken without regard to food.
3 DOSAGE FORMS AND STRENGTHS
Paricalcitol capsules are available as 1 mcg, 2 mcg, and 4 mcg soft gelatin capsules.
- 1 mcg: oval, gray capsule imprinted with “PA1”
- 2 mcg: oval, orange-brown capsule imprinted with “PA2”
- 4 mcg: oval, yellow capsule imprinted with “PA4”
4 CONTRAINDICATIONS
Paricalcitol capsules should not be given to patients with evidence of
-
hypercalcemia or
-
vitamin D toxicity [see Warnings and Precautions (5.1) ].
5 WARNINGS AND PRECAUTIONS
Excessive administration of vitamin D compounds, including paricalcitol capsules, can cause over suppression of PTH, hypercalcemia, hypercalciuria, hyperphosphatemia, and adynamic bone disease.
5.1 Hypercalcemia
Progressive hypercalcemia due to overdosage of vitamin D and its metabolites may be so severe as to require emergency attention [see Overdosage (10) ]. Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate the action of digitalis. Chronic hypercalcemia can lead to generalized vascular calcification and other soft-tissue calcification. Concomitant administration of high doses of calcium-containing preparations or thiazide diuretics with paricalcitol may increase the risk of hypercalcemia. High intake of calcium and phosphate concomitant with vitamin D compounds may lead to serum abnormalities requiring more frequent patient monitoring and individualized dose titration. Patients also should be informed about the symptoms of elevated calcium, which include feeling tired, difficulty thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination and weight loss.
Prescription-based doses of vitamin D and its derivatives should be withheld during paricalcitol treatment to avoid hypercalcemia.
5.2 Digitalis Toxicity
Digitalis toxicity is potentiated by hypercalcemia of any cause. Use caution when paricalcitol capsules are prescribed concomitantly with digitalis compounds.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.